Postprandial changes in gastrointestinal function and transit in cystic fibrosis assessed by Magnetic Resonance Imaging.

Background: Cystic fibrosis (CF) is a multi-system genetic disorder affecting >72,000 people worldwide. Most CF patients experience gastrointestinal symptoms and can develop complications. However, the mechanisms of CF gut disease are not well understood. We evaluated gut function and transit in CF using magnetic resonance imaging (MRI). We hypothesised oro-caecal transit time (OCTT) is longer in CF; with lower small bowel water content (SBWC).
Methods: Twelve CF patients aged 12-40 years and 12 age and sex-matched controls underwent serial MRIs over 1 day with standardised meals. The primary endpoint was OCTT, assessed by the appearance of a food bolus in the caecum. Other measures included corrected SBWC and corrected colonic volume (both area under the curve, AUC), gastric half-emptying time and gastrointestinal symptoms.
Results: OCTT was longer in CF (CF 330 mins [270, >360] vs. controls 210 mins [173, 315], p = 0.04), with no difference in gastric half-emptying times. Corrected SBWC was higher in CF (CF 62 L.min/m ² [36, 80] vs. controls 34 L.min/m ² [28, 41], p = 0.021); minimal postprandial decrease between T240 and T300 (CF 13 mL/m ² [-13, 57] vs. controls 102 mL/m ² [67, 108], p = 0.002) suggests impaired ileal emptying. Corrected colonic volumes were higher in CF (CF 186 L.min/m ² [167, 206] vs. controls 123 L.min/m ² [89, 146], p = 0.012). There were no differences in gastrointestinal symptoms.
Conclusions: MRI provides novel insights into CF pathophysiology. Sub-clinical ileal obstruction may be more prevalent than previously thought. Gastrointestinal MRI shows promise as an investigational tool in CF.
Competing Interests: Declaration of Competing Interest NSD, CLD, LM, LB, HLB, AJ, PG have nothing to disclose. CN, JGM and GM report grants and speaker honorarium from Vertex, outside the submitted work. APP reports grants from Thrasher Research Fund, grants from Action for A-T, grants from Health Education East Midlands, outside the submitted work; these grants are for the development of lung MRI in children and infants. RS reports grants from Zespri International Ltd and Sanofi-Aventis, as well as lecturing fees from Menarini and Alfawasserman, outside the submitted work. ARS reports grants from Vertex, as well as speaker honoraria and expenses from Teva and Novartis and personal fees from Vertex, outside the submitted work. In addition, ARS has a patent issued “Alkyl quinolones as biomarkers of Pseudomonas aeruginosa infection and uses thereof”.
(Copyright © 2020. Published by Elsevier B.V.)